| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
ITIC-4F functions as an electron acceptor in organic photovoltaic devices. Its primary "target" is the electron donor material in the active layer of the solar cell, where it facilitates the separation and transport of charge carriers. As a non-fullerene acceptor, it offers advantages over traditional fullerene-based acceptors, such as tunable energy levels and improved light absorption. The compound is used in materials science research to develop high-efficiency solar cells.
|
|---|---|
| ln Vitro |
In vitro, ITIC-4F demonstrates wide applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs). Its performance as an electron acceptor is typically evaluated in device physics studies, where it is incorporated into solar cell architectures and characterized for power conversion efficiency, fill factor, open-circuit voltage, and short-circuit current. Its fluorinated structure contributes to its favorable electronic properties.
|
| ln Vivo |
In vivo studies of ITIC-4F are not applicable, as it is a material for organic electronics rather than a therapeutic or biological agent. The compound is used in materials science and engineering applications, not in biological systems. Its performance is assessed in the context of device fabrication and characterization, not in animal models.
|
| Enzyme Assay |
For in vitro characterization, ITIC-4F is evaluated using materials science techniques rather than biological assays. Its optical properties are assessed using UV-Vis absorption spectroscopy and photoluminescence spectroscopy. Its electrochemical properties are characterized using cyclic voltammetry to determine energy levels. Its performance in solar cells is evaluated by fabricating devices and measuring current-voltage characteristics under simulated solar illumination.
|
| Cell Assay |
For in vitro cellular experiments, ITIC-4F is not applicable, as it is a material for organic electronics rather than a biological or pharmaceutical agent. The compound is not tested in cell-based assays. Its applications are in the field of materials science and photovoltaics, not in cellular or molecular biology.
|
| Animal Protocol |
For in vivo animal experiments, ITIC-4F is not applicable, as it is a material for organic electronics rather than a therapeutic agent. The compound is not administered to animals. Its use is confined to materials science research and device fabrication.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ITIC-4F are not applicable, as it is a material for organic electronics rather than a therapeutic agent. The compound is not administered to animals or humans. Its stability and solubility in organic solvents are important for device fabrication, but its biological pharmacokinetics are not relevant.
|
| Toxicity/Toxicokinetics |
Toxicological data for ITIC-4F are limited, as it is a material for organic electronics rather than a therapeutic or biological agent. As with all research chemicals, appropriate safety precautions should be taken when handling the compound, including the use of personal protective equipment and adherence to institutional safety guidelines.
|
| Additional Infomation |
ITIC-4F is a research material used in organic photovoltaics and perovskite solar cells. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is an IDTT-based non-fullerene electron acceptor with broad applicability in high-efficiency solar cells.
|
| Molecular Formula |
C94H78F4N4O2S4
|
|---|---|
| Molecular Weight |
1499.9044
|
| Exact Mass |
1499.497
|
| CAS # |
2097998-59-7
|
| PubChem CID |
135395313
|
| Appearance |
Brown to black solid powder
|
| Density |
1.311±0.06 g/cm3(Predicted)
|
| LogP |
27.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
108
|
| Complexity |
3210
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C2C([H])=C(C([H])=C3C(C4=C([H])C(=C(C([H])=C4/C/3=C(/C#N)\C#N)F)F)=O)SC=2C2=C1C1C([H])=C3C(=C([H])C=1C2(C1C([H])=C([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=C([H])C=1[H])C1C([H])=C([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=C([H])C=1[H])C1=C(C2=C(C([H])=C(C([H])=C4C(C5=C([H])C(=C(C([H])=C5/C/4=C(/C#N)\C#N)F)F)=O)S2)S1)C3(C1C([H])=C([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=C([H])C=1[H])C1C([H])=C([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=C([H])C=1[H]
|
| InChi Key |
JOZQXSUYCMNTCH-ODDCUFEPSA-N
|
| InChi Code |
InChI=1S/C94H78F4N4O2S4/c1-5-9-13-17-21-55-25-33-61(34-26-55)93(62-35-27-56(28-36-62)22-18-14-10-6-2)75-45-72-76(46-71(75)89-85(93)91-81(107-89)43-65(105-91)41-73-83(59(51-99)52-100)67-47-77(95)79(97)49-69(67)87(73)103)94(63-37-29-57(30-38-63)23-19-15-11-7-3,64-39-31-58(32-40-64)24-20-16-12-8-4)86-90(72)108-82-44-66(106-92(82)86)42-74-84(60(53-101)54-102)68-48-78(96)80(98)50-70(68)88(74)104/h25-50H,5-24H2,1-4H3/b73-41-,74-42-
|
| Chemical Name |
2-[(2Z)-2-[[20-[(Z)-[1-(dicyanomethylidene)-5,6-difluoro-3-oxoinden-2-ylidene]methyl]-12,12,24,24-tetrakis(4-hexylphenyl)-5,9,17,21-tetrathiaheptacyclo[13.9.0.03,13.04,11.06,10.016,23.018,22]tetracosa-1(15),2,4(11),6(10),7,13,16(23),18(22),19-nonaen-8-yl]methylidene]-5,6-difluoro-3-oxoinden-1-ylidene]propanedinitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6667 mL | 3.3336 mL | 6.6671 mL | |
| 5 mM | 0.1333 mL | 0.6667 mL | 1.3334 mL | |
| 10 mM | 0.0667 mL | 0.3334 mL | 0.6667 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
